ATE434445T1 - Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper - Google Patents

Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper

Info

Publication number
ATE434445T1
ATE434445T1 AT04814203T AT04814203T ATE434445T1 AT E434445 T1 ATE434445 T1 AT E434445T1 AT 04814203 T AT04814203 T AT 04814203T AT 04814203 T AT04814203 T AT 04814203T AT E434445 T1 ATE434445 T1 AT E434445T1
Authority
AT
Austria
Prior art keywords
cancer treatment
tumors
carriers
agents
pharmaceutical compounds
Prior art date
Application number
AT04814203T
Other languages
English (en)
Inventor
Henry J Smith
James R Smith
Original Assignee
Henry J Smith
James R Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry J Smith, James R Smith filed Critical Henry J Smith
Application granted granted Critical
Publication of ATE434445T1 publication Critical patent/ATE434445T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04814203T 2003-12-24 2004-12-15 Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper ATE434445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/745,308 US7799327B2 (en) 2003-12-24 2003-12-24 Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
PCT/US2004/041992 WO2005065710A1 (en) 2003-12-24 2004-12-15 Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment

Publications (1)

Publication Number Publication Date
ATE434445T1 true ATE434445T1 (de) 2009-07-15

Family

ID=34710601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04814203T ATE434445T1 (de) 2003-12-24 2004-12-15 Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper

Country Status (6)

Country Link
US (1) US7799327B2 (de)
EP (1) EP1706145B1 (de)
AT (1) ATE434445T1 (de)
CA (1) CA2551913A1 (de)
DE (1) DE602004021722D1 (de)
WO (1) WO2005065710A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617637C (en) 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2285409B1 (de) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1-alpha-antikörper
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
US20100086585A1 (en) * 2008-10-06 2010-04-08 Henry John Smith Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases
EP2582391B1 (de) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis-behandlung
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US9102709B1 (en) * 2011-07-08 2015-08-11 Biogen Ma Inc. Regeneration of chromatography material
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20150290386A1 (en) * 2014-04-10 2015-10-15 Xianfeng Frank Zhao Extracorporeal autoimmune solution therapy (east)
EP3582813A4 (de) 2017-02-16 2020-12-30 XBiotech, Inc Behandlung von hidradenitis suppurativa
US20220008636A1 (en) * 2020-07-12 2022-01-13 Henry J. Smith Apheresis to remove interfering substances
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
US20250235594A1 (en) * 2024-01-22 2025-07-24 Henry J. Smith Targeted apheresis to treat inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000084A1 (en) * 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5881048A (en) * 1996-11-25 1999-03-09 Mci Communication Corporation Method and apparatus for determining maximum network failure spans forrestoration
US6075766A (en) * 1996-11-26 2000-06-13 Mci Communications Corporation Method and apparatus for identifying restoral routes in a network
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6982951B2 (en) * 2000-12-21 2006-01-03 At&T Corp. Method for selecting a restoration path in a mesh network
US20020086276A1 (en) * 2000-12-28 2002-07-04 Srivastava Pramod K. Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands
US6904462B1 (en) * 2001-07-06 2005-06-07 Ciena Corporation Method and system for allocating protection path resources
JP3705222B2 (ja) * 2002-02-06 2005-10-12 日本電気株式会社 パス設定方法及びそれを用いる通信ネットワーク並びにノード装置
US7406074B2 (en) * 2002-07-12 2008-07-29 Lucent Technologies Inc. Bundling messages in communication networks

Also Published As

Publication number Publication date
DE602004021722D1 (de) 2009-08-06
EP1706145A1 (de) 2006-10-04
US20050147603A1 (en) 2005-07-07
WO2005065710A1 (en) 2005-07-21
EP1706145B1 (de) 2009-06-24
CA2551913A1 (en) 2005-07-21
US7799327B2 (en) 2010-09-21
EP1706145A4 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE434445T1 (de) Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper
Walker et al. Brain and spinal tumors of childhood
Nicholson et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
CY1123110T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
Videtic et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas
Laksitorini et al. Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood–brain barrier permeability
CN121824666A (zh) 靶向psma的nir染料及其应用
Evangelista et al. Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of theliterature
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
DE602004017290D1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
Xu et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer
Kim et al. Procarbazine and CCNU chemotherapy for recurrent glioblastoma with MGMT promoter methylation
Jian et al. Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy
Ghai et al. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F] FDG and [64Cu] Cu-LLP2A PET
EP1532162A4 (de) Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
BR112021025124A2 (pt) Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso
DE60330914D1 (de) Arzneimittel mit shikonin als wirkstoff
WO2005113720A3 (en) A strategy for designing patient-specific anti-cancer drugs
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
Li et al. Pharmacokinetics of Agelastatin A in the central nervous system
Moar et al. Evolution of targeted therapies in cancer: opportunities and challenges
Kool et al. INSP-15. ITCC-P4: a sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughput in vivo testing
DE60033697D1 (de) Radiomarkierte vip-analoge zur diagnose und therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties